Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?

Eur Heart J. 2022 Nov 14;43(43):4599-4600. doi: 10.1093/eurheartj/ehac219.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Acute Coronary Syndrome* / genetics
  • Clopidogrel
  • Cytochrome P-450 CYP2C19 / genetics
  • Genotype
  • Humans
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prasugrel Hydrochloride

Substances

  • Clopidogrel
  • Prasugrel Hydrochloride
  • Platelet Aggregation Inhibitors
  • Cytochrome P-450 CYP2C19